Clinical Investigation| Volume 355, ISSUE 5, P418-424, May 2018

Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy



      There is a lack of research on the effect of low dose of angiotensin receptor blockers combined with spironolactone, and the effect of high dose of angiotensin receptor blockers alone on the urinary albumin excretion rate (UAER) in elderly patients with early type 2 diabetic nephropathy (DN).


      We conducted a prospective, randomized, open-label, parallel-controlled study that included 244 elderly patients with early DN and mild-to-moderate essential hypertension. Patients were randomly divided into 4 groups: low-dose irbesartan (group A), high-dose irbesartan (group B), low-dose irbesartan combined with spironolactone (group C) and high-dose irbesartan combined with spironolactone (group D). Changes in UAER, serum potassium and blood pressure were compared.


      There were no statistical differences in the baseline characteristics among groups. Furthermore, no significant difference in blood pressure before and after treatment was found among different groups. After 72-week treatment, UAER in group D was lower compared to group A and B (P < 0.05). Meanwhile, compared with group B, UAER in group C decreased significantly (P < 0.05). Additionally, significantly higher serum potassium was found in group D compared to other groups (P < 0.05). Also, group D had the highest count of patients who withdrew from the study due to hyperkalemia compared to other groups (P < 0.05).


      Our results indicate high-dose irbesartan combined with spironolactone may be more efficient in reducing UAER in elderly patients with early DN, but this treatment could cause hyperkalemia. Low-dose irbesartan combined with spironolactone was shown to be safer and more effective in decreasing UAER compared to high-dose irbesartan.

      Key Indexing Terms

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Chinese Diabetes Society.
        Guidelines for prevention and treatment of type 2 diabetes in China.
        Chin J Diabetes Mellitus (Article in Chinese). 2014; 7: 447-498
        • Parving H.H.
        • Lehnert H.
        • Brochner-Mortensen J.
        • et al.
        The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
        N Engl J Med. 2001; 345: 870-878
        • Schjoedt K.J.
        • Andersen S.
        • Rossing P.
        • et al.
        Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate.
        Diabetologia. 2004; 47: 1936-1939
        • Kato S.
        • Maruyama S.
        • Makino H.
        • et al.
        Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
        Clin Exp Nephrol. 2015; 19: 1098-1106
        • Mehdi U.F.
        • Adams-Huet B.
        • Raskin P.
        • et al.
        Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.
        J Am Soc Nephrol. 2009; 20: 2641-2650
      1. Writing Group of 2010 Chinese Guidelines for the Management of Hypertension. 2010 Chinese guidelines for the management of hypertension. Chin J Cardiol (Article in Chinese) 2011; 39: 579-616.

        • Chinese Society of Endocrinology.
        Expert consensus of HbA1c control target for Chinese adult with type 2 diabetes.
        Chin J Endocrinol Metab (Article in Chinese). 2011; 27: 371-374
        • Levey A.S.
        • Stevens L.A.
        • Schmid C.H.
        • et al.
        A new equation to estimate glomerular filtration rate.
        Ann Intern Med. 2009; 150: 604-612
        • Liu P.
        • Liu R.
        • Chen X.
        • et al.
        Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study.
        Curr Med Res Opin. 2015; 31: 2233-2240
        • Chinese Diabetes Society.
        Expert consensus on prevention and treatment of diabetic nephropathy (2014).
        Chin J Diabetes Mellitus (Article in Chinese). 2014; 6: 792-801
        • Mavrakanas T.A.
        • Gariani K.
        • Martin P.Y.
        Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review.
        Eur J Intern Med. 2014; 25: 173-176
        • Saito M.
        • Takada M.
        • Hirooka K.
        • et al.
        Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
        J Clin Pharm Ther. 2005; 30: 603-610
        • Esteghamati A.
        • Noshad S.
        • Jarrah S.
        • et al.
        Long-term effects of addition of mineralocorticoid receptor antagonist to angiotensin 2 receptor blocker in patients with diabetic nephropathy: a randomized clinical trial.
        Nephrol Dial Transplant. 2013; 28: 2823-2833
        • van den Meirackera A.H.
        • Baggen R.G.
        • Paulia S.
        • et al.
        Spironolactone in type 2 diabetic nephropathy: effects on proteinuria, blood pressure and renal function.
        J Hypertens. 2006; 24: 2285-2292
        • Rossing K.
        • Schjoedt K.J.
        • Smidt U.M.
        • et al.
        Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study.
        Diabetes Care. 2005; 28: 2106-2112
        • Batterink J.
        • Stabler S.N.
        • Tejani A.M.
        • et al.
        Spironolactone for hypertension.
        Cochrane Database Syst Rev. 2010; 8 (CD008169)
        • Hanazawa T.
        • Obara T.
        • Ogasawara K.
        • et al.
        Low-dose and very low-dose spironolactone in combination therapy for essential hypertension: evaluation by self-measurement of blood pressure at home.
        Clin Exp Hypertens. 2011; 33: 427-436
        • Chang Y.H.
        • Lei C.C.
        • Lin K.C.
        • et al.
        Serum uric acid level as an indicator for CKD regression and progression in patients with type 2 diabetes mellitus—a 4.6-year cohort study.
        Diabetes Metab Res Rev. 2016; 32: 557-564
        • Liu P.
        • Chen Y.
        • Wang B.
        • et al.
        Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study.
        Clin Endocrinol (Oxf). 2015; 83: 475-482
        • Endocrine branch of the Chinese Medical Association.
        China expert consensus on treatment of hyperuricemia and gout.
        Chin J Endocrinol Metab (Article in Chinese). 2013; 29: 913-920
        • Nishida Y.
        • Takahashi Y.
        • Susa N.
        • et al.
        Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
        Cardiovasc Diabetol. 2013; 12: 159
        • Wolff M.L.
        • Cruz J.L.
        • Vanderman A.J.
        • et al.
        The effect of angiotensin II receptor blockers on hyperuricemia.
        Adv Chronic Dis. 2015; 6: 339-346
        • Lewis E.J.
        • Hunsicker L.G.
        • Clarke W.R.
        • et al.
        Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
        N Engl J Med. 2001; 345: 851-860